重組表皮生長因子聯(lián)合莫匹羅星在鼓膜修補(bǔ)術(shù)中的臨床應(yīng)用效果(1)
[摘要] 目的 探討重組表皮生長因子聯(lián)合莫匹羅星在鼓膜修補(bǔ)術(shù)中的臨床應(yīng)用效果。 方法 選擇2013年1～12月在本院接受鼓膜修補(bǔ)術(shù)治療的60例患者為研究對(duì)象，隨機(jī)分為2組，各30例，對(duì)照組患者行明膠海綿單純外貼手術(shù)，試驗(yàn)組患者行涂有重組表皮生長因子+莫匹羅星混合物的明膠海綿外貼手術(shù)，比較兩組治療效果及并發(fā)癥情況。 結(jié)果 試驗(yàn)組治愈率為93.33%，對(duì)照組治愈率為86.67%，兩組比較，差異無統(tǒng)計(jì)學(xué)意義(P>0.05)；試驗(yàn)組并發(fā)癥發(fā)生率為3.3%，低于對(duì)照組的20%，差異有統(tǒng)計(jì)學(xué)意義(P<0.05)；兩組術(shù)后聽力改善及鼓膜愈合時(shí)間比較，差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。 結(jié)論 鼓膜修補(bǔ)術(shù)中應(yīng)用重組表皮生長因子聯(lián)合莫匹羅星，能有效促進(jìn)創(chuàng)面愈合，減少并發(fā)癥，提高手術(shù)成功率。
[關(guān)鍵詞] 鼓膜修補(bǔ)術(shù)；重組表皮生長因子；莫匹羅星；應(yīng)用效果
[中圖分類號(hào)] R764.9+2 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-4721(2015)05(b)-0100-03
Clinical application effect of recombinant endothelial growth factor combined with mupirocin in myringoplasty
YUAN Zu-jun1 LIU Xiao-fei2
1.Department of Otorhinolaryngology，the First People′s Hospital of Ji′an City in Jiangxi Province，Ji′an 343000，China；2.Department of Otorhinolaryngology，People′s Hospital of Wanan County in Jiangxi Province，Wanan 343800，China
[Abstract] Objective To explore the clinical application effect of recombinant epidermal growth factor (REGF) combined with mupirocin in myringoplasty. Methods 60 patients accepted myringoplasty in our hospital from January to December in 2013 were selected as research objects.They were evenly divided into two groups in random.In control group， patients were treated by external application of gelatin sponge alone，while external application of gelatin sponge covered with REGF combined with mupirocin was adopted to experimental group.The therapeutic effect and complications between two groups was compared respectively. Results The cure rate in experimental group was 93.33%，while in control group，the rate was 86.67%，with no statistical differenc(P>0.05).In experimental group，the incidence of complication was 3.3%，while in control group，the rate was 20%，with statistical difference(P<0.05).In addition，there were statistical differences in postoperative hearing improvement and healing time of tympanic membrane(P<0.05). Conclusion Recombinant endothelial growth factor combined with mupirocin in myringoplasty can effectively promote wound healing and reduce complications and improve the surgical successful rate.
[Key words] Myringoplasty；Recombinant epidermal growth factor (REGF)；Mupirocin；Application effect
傳統(tǒng)治療鼓膜穿孔以早期預(yù)防感染、自然愈合為主，易出現(xiàn)中耳化膿性炎癥等，造成嚴(yán)重后果[1-2]。為此建議擇期行手術(shù)治療，促進(jìn)創(chuàng)面早期愈合[3-5]。本研究對(duì)本院收治的鼓膜穿孔患者行重組表皮生長因子+莫匹羅星外貼法鼓膜修補(bǔ)術(shù)，效果明顯。
1 資料與方法
1.1 一般資料
選擇2013年1～12月在本院行鼓膜修補(bǔ)術(shù)治療的60例鼓膜穿孔患者為研究對(duì)象，納入標(biāo)準(zhǔn)：①中央性穿孔，直徑2～4 mm，干耳>半個(gè)月；②咽鼓管、鼻咽部檢查正常；③聽力為混合型或傳導(dǎo)性耳聾，氣導(dǎo)聽閾≤45 dB；④自愿簽署知情同意書。排除標(biāo)準(zhǔn)：①顱腦損傷、咽鼓管功能障礙；②感音神經(jīng)性聾且眩暈；③肝、腎功能嚴(yán)重障礙。其中男性32例，女性28例，年齡20～58歲，平均(40.2±2.5)歲。病因：外傷引起22例，中耳炎引起20例，外界聲音刺激引起5例，其他13例。隨機(jī)將60例患者分為對(duì)照組和試驗(yàn)組，各30例，兩組患者的性別、年齡、病因等一般資料比較，差異無統(tǒng)計(jì)學(xué)意義(P>0.05)，具有可比性。 (袁祖均 劉小飛)
[關(guān)鍵詞] 鼓膜修補(bǔ)術(shù)；重組表皮生長因子；莫匹羅星；應(yīng)用效果
[中圖分類號(hào)] R764.9+2 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1674-4721(2015)05(b)-0100-03
Clinical application effect of recombinant endothelial growth factor combined with mupirocin in myringoplasty
YUAN Zu-jun1 LIU Xiao-fei2
1.Department of Otorhinolaryngology，the First People′s Hospital of Ji′an City in Jiangxi Province，Ji′an 343000，China；2.Department of Otorhinolaryngology，People′s Hospital of Wanan County in Jiangxi Province，Wanan 343800，China
[Abstract] Objective To explore the clinical application effect of recombinant epidermal growth factor (REGF) combined with mupirocin in myringoplasty. Methods 60 patients accepted myringoplasty in our hospital from January to December in 2013 were selected as research objects.They were evenly divided into two groups in random.In control group， patients were treated by external application of gelatin sponge alone，while external application of gelatin sponge covered with REGF combined with mupirocin was adopted to experimental group.The therapeutic effect and complications between two groups was compared respectively. Results The cure rate in experimental group was 93.33%，while in control group，the rate was 86.67%，with no statistical differenc(P>0.05).In experimental group，the incidence of complication was 3.3%，while in control group，the rate was 20%，with statistical difference(P<0.05).In addition，there were statistical differences in postoperative hearing improvement and healing time of tympanic membrane(P<0.05). Conclusion Recombinant endothelial growth factor combined with mupirocin in myringoplasty can effectively promote wound healing and reduce complications and improve the surgical successful rate.
[Key words] Myringoplasty；Recombinant epidermal growth factor (REGF)；Mupirocin；Application effect
傳統(tǒng)治療鼓膜穿孔以早期預(yù)防感染、自然愈合為主，易出現(xiàn)中耳化膿性炎癥等，造成嚴(yán)重后果[1-2]。為此建議擇期行手術(shù)治療，促進(jìn)創(chuàng)面早期愈合[3-5]。本研究對(duì)本院收治的鼓膜穿孔患者行重組表皮生長因子+莫匹羅星外貼法鼓膜修補(bǔ)術(shù)，效果明顯。
1 資料與方法
1.1 一般資料
選擇2013年1～12月在本院行鼓膜修補(bǔ)術(shù)治療的60例鼓膜穿孔患者為研究對(duì)象，納入標(biāo)準(zhǔn)：①中央性穿孔，直徑2～4 mm，干耳>半個(gè)月；②咽鼓管、鼻咽部檢查正常；③聽力為混合型或傳導(dǎo)性耳聾，氣導(dǎo)聽閾≤45 dB；④自愿簽署知情同意書。排除標(biāo)準(zhǔn)：①顱腦損傷、咽鼓管功能障礙；②感音神經(jīng)性聾且眩暈；③肝、腎功能嚴(yán)重障礙。其中男性32例，女性28例，年齡20～58歲，平均(40.2±2.5)歲。病因：外傷引起22例，中耳炎引起20例，外界聲音刺激引起5例，其他13例。隨機(jī)將60例患者分為對(duì)照組和試驗(yàn)組，各30例，兩組患者的性別、年齡、病因等一般資料比較，差異無統(tǒng)計(jì)學(xué)意義(P>0.05)，具有可比性。 (袁祖均 劉小飛)